
Angiotensin-converting enzyme 2 (ACE2) is an enzymatically active homologue of angiotensin-converting enzyme that degrades angiotensin I, angiotensin II, and other peptides. Recent studies have shown that under pathologic conditions, ACE2 expression in the kidney is altered. In this review, we briefly summarize recent studies dealing with pharmacologic interventions that modulate ACE2 expression. ACE2 amplification may have a potential therapeutic role for kidney disease and hypertension.
Angiotensin II, Angiotensin-Converting Enzyme Inhibitors, Peptidyl-Dipeptidase A, Article, Receptor, Angiotensin, Type 1, Renin-Angiotensin System, Hypertension, Disease Progression, Humans, Angiotensin-Converting Enzyme 2, Angiotensin I, Angiotensin II Type 1 Receptor Blockers, Antihypertensive Agents
Angiotensin II, Angiotensin-Converting Enzyme Inhibitors, Peptidyl-Dipeptidase A, Article, Receptor, Angiotensin, Type 1, Renin-Angiotensin System, Hypertension, Disease Progression, Humans, Angiotensin-Converting Enzyme 2, Angiotensin I, Angiotensin II Type 1 Receptor Blockers, Antihypertensive Agents
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 73 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 1% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
